Cases,Complications,Comorbidity and Costs of Diabetes in UK: Is Treatment Falling Wide of the Mark?

Currie CJ Peters JR Evans M. Dispensing patterns and financial costs of glucose-lowering therapies in the UK from 2000 to 2008. Diabet Med 2010;27:744–52.

Currie CJ Gale EAM Poole CD . Estimation of primary care treatment costs and treatment efficacy for people with Type 1 and Type 2 diabetes in the United Kingdom from 1997 to 2007. Diabet Med 2010; 27:938–48.

Morgan CL Peters JR Currie CJ . The changing prevalence of diagnosed diabetes and its associated vascular complications in a large region of the UK. Diabet Med 2010;27:673–8.

Morgan CL Peters JR Dixon S Currie CJ . Estimated costs of acute hospital care for people with diabetes in the United Kingdom: a routine record linkage study in a large region. Diabet Med 2010;27:1066–73.

Gray AM . Diabetes: costs and cost-effectiveness. Diabet Med 2010;27:971–2.

Gale EAM . Diabetes in the UK: time for a reality check? Diabet Med 2010;27:973–6.

Currie CJ Kraus D Morgan CL NHS acute sector expenditure for diabetes: the present, future, and excess in-patient cost of care. Diabet Med 1997;14:686–92.

Evans JMM Barnett KN Ogston SA Morris AD . Increasing prevalence of type 2 diabetes in a Scottish population: effect of increasing incidence or decreasing mortality? Diabetologia 2007;50:729–32.

National Diabetes Audit Executive Summary 2008–2009. Key findings about the quality of care for people with diabetes in England and Wales. Report for the audit period 2008–2009. www.ic.nhs.uk/webfiles/Services/NCASP/audits%20and%20reports/National%20Diabetes%20Audit%20(NDA)%20Executive%20Summary%202008–2009.pdf (accessed 28 August 2010).

Waugh N Cummins E Royle P Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess 2010;14:1–248.

NICE short clinical guideline 87. Type 2 diabetes: newer agents for blood glucose control of type 2 diabetes. May 2009. www.nice.org.uk/nicemedia/live/12165/44318/44318.pdf (accessed 30 August 2010).

The NHS Information Centre, Prescribing Support and Primary Care Services. Prescribing for Diabetes in England: 2004/05 to 2009/10. July 2010. www.ic.nhs.uk/statistics-and-data-collections/primary-care/prescriptions/prescribing-for-diabetes-in-england-2004–05-to-2009–10 (accessed 30 August 2010).

Nissen SE Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457–71.

MHRA. Rosiglitazone and pioglitazone: cardiovascular safety, December 2007. Drug Safety Update 2007;1(5) www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/CON2033216 (accessed 30 August 2010).

MHRA. Rosiglitazone: new contraindications and warnings, February 2008. Drug Safety Update 2008;1(7) www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/CON2033917 (accessed 30 August 2010).

National Prescribing Centre. Medicines management options for local implementation. Key therapeutic topics 201 0/11. July 2010. www.pulsetoday.co.uk/Journals/Medical/Pulse/2010_August_11/attachments/NPC%20report.pdf (accessed 31 August 2010).

Department of Health. Equity and Excellence: Liberating the NHS. UK Coalition Government White Paper www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_117353 (accessed 28 August 2010).

NHS. Health Survey for England 2008: Physical Activity and Fitness. London: NHS Information Centre, 2009. www.ic.nhs.uk/webfiles/publications/HSE/HSE08/HSE_08_Summary_of_key_findings.pdf (accessed 1 September 2010).

Mullard A. Commentary: GLP-1 receptor agonists vie for diabetes market share. Scrip Intelligence 2010;(3506):16.

Bottomley JM . Economic costs of diabetes in the US in 2007: Implications for Europe. Br J Diabetes Vasc Dis 2008;8:96–100.

Bottomley JM Raymond FD . Pharmacoeconomic issues for diabetes therapy. Best Pract Res Clin Endocrinol Metab 2007;21:657–85.

Towse A Garrison LP Jr. Can't get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics 2010;28:93–102.

NICE. NICE NEWS 2010. NHS organisations to be named in report into the uptake of NICE-approved drugs on the NHS, 20 August 2010. www.nice.org.uk/newsroom/newsReportUptakeOfNICEApprovedDrugss.jsp (accessed on 28 August 2010).

NICE Clinical Guideline 87. Type 2 diabetes: newer agents (a partial update of CG 66). Cost template. http://guidance.nice.org.uk/CG87/CostingTemplate/xls/English (accessed 30 August 2010).

NICE. NICE announces 2011/12 QOF indicators. 4 August 2010. NICE News. www.nice.org.uk/newsroom/news/2011–12qofindicators.jsp (accessed 31 August 2010).

NICE. Quality standards in development. NICE, 2010. www.nice.org.uk/aboutnice/qualitystandards/indevelopment/qualitystandardsinde-velopment.jsp (accessed 31 August 2010)